Top

11-03-2024 | Ramucirumab | Original Research Article

Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients

Authors: Keisuke Onoi, Tadaaki Yamada, Kenji Morimoto, Hayato Kawachi, Rei Tsutsumi, Takayuki Takeda, Asuka Okada, Nobuyo Tamiya, Yusuke Chihara, Shinsuke Shiotsu, Yoshizumi Takemura, Takahiro Yamada, Isao Hasegawa, Yuki Katayama, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama

Published in: Targeted Oncology

Abstract

Background

Combination therapy with docetaxel (DTX) and ramucirumab (RAM) has been used as a second-line treatment for advanced or recurrent lung cancer. However, there is insufficient evidence regarding the safety of angiogenesis inhibitors in older patients.

Objective

This multicenter retrospective study aimed to investigate the efficacy and safety of second-line treatment regimens in older patients with advanced or recurrent non-small cell lung cancer (NSCLC).

Patients and Methods

We retrospectively analyzed 145 patients aged ≥ 70 years with advanced or recurrent NSCLC treated with second-line chemotherapy after platinum-based therapy between April 1, 2016, and March 31, 2021. Patients were subdivided into the DTX + RAM (n = 38) and single-agent (n = 107) groups.

Results

The median time to treatment failure was 6.3 months (95% confidence interval [CI] 3.6–9.6) in the DTX + RAM group and 2.3 months (95% CI 1.7–3.0) in the single-agent group (p < 0.01). The median overall survival was 15.9 months (95% CI 12.3–Not Achieved) in the DTX + RAM group and 9.4 months (95% CI 6.9–15.1) in the single-agent group (p = 0.01). Grade ≥ 3 adverse events frequency was not significantly different between the two groups, except for edema. Patients in the DTX + RAM group who did not discontinue treatment owing to adverse events exhibited the most favorable prognosis.

Conclusions

These findings suggest that the DTX + RAM combination is an effective second-line therapy for older patients with advanced or recurrent NSCLC, offering favorable efficacy without treatment discontinuation owing to adverse events.

Available only for authorised users

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763.CrossRefPubMed

Marosi C, Köller M. Challenge of cancer in the elderly. ESMO Open. 2016;1:e000020. https://doi.org/10.1136/esmoopen-2015-000020.CrossRefPubMedPubMedCentral

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92. https://doi.org/10.1056/NEJMoa1801005.CrossRefPubMed

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301. https://doi.org/10.1056/NEJMoa1716948.CrossRefPubMed

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–37. https://doi.org/10.1016/S1470-2045(19)30167-6.CrossRefPubMed

Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198–211. https://doi.org/10.1016/S1470-2045(20)30641-0.CrossRefPubMed

Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–88. https://doi.org/10.1016/S0140-6736(11)60780-0.CrossRefPubMed

Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, et al. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (Capital): a randomised, multicentre, open-label, phase 3 trial. Lancet Healthy Longev. 2021;2:e791–800. https://doi.org/10.1016/S2666-7568(21)00255-5.CrossRefPubMed

Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, et al. Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:e196828. https://doi.org/10.1001/jamaoncol.2019.6828.CrossRefPubMedPubMedCentral

10.

Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 2016;99:186–93. https://doi.org/10.1016/j.lungcan.2016.07.019.CrossRefPubMed

11.

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665–73. https://doi.org/10.1016/S0140-6736(14)60845-X.CrossRefPubMed

12.

Kubo T, Watanabe H, Ninomiya K, Kudo K, Minami D, Murakami E, et al. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Jpn J Clin Oncol. 2020;50:1447–53. https://doi.org/10.1093/jjco/hyaa152.CrossRefPubMed

13.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244.CrossRefPubMed

14.

Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26:60–5. https://doi.org/10.1200/JCO.2007.13.1144.CrossRefPubMed

15.

Wozniak AJ, Kosty MP, Jahanzeb M, Brahmer JR, Spigel DR, Leon L, et al. Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. Clin Oncol (R Coll Radiol). 2015;27:187–96. https://doi.org/10.1016/j.clon.2014.12.002.CrossRefPubMed

16.

Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, Groen H, et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol. 2012;7:203–11. https://doi.org/10.1097/JTO.0b013e3182370e02.CrossRefPubMed

17.

Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Kanematsu T, et al. Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Transl Lung Cancer Res. 2019;8:450–60. https://doi.org/10.21037/tlcr.2019.08.07.CrossRefPubMedPubMedCentral

18.

Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, et al. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: a retrospective study. Thorac Cancer. 2022;13:173–81. https://doi.org/10.1111/1759-7714.14236.CrossRefPubMed

19.

Katayama Y, Yamada T, Sawada R, Kawachi H, Morimoto K, Watanabe S, et al. Prospective observational study of ramucirumab plus docetaxel after combined chemoimmunotherapy in patients with non-small-cell lung cancer. Oncologist. 2024;2024:oyae001. https://doi.org/10.1093/oncolo/oyae001.CrossRef

20.

Seto Y, Kaneko Y, Mouri T, Fujii H, Tanaka S, Shiotsu S, et al. Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study. Transl Lung Cancer Res. 2021;10:193–201. https://doi.org/10.21037/tlcr-20-894.CrossRefPubMedPubMedCentral

21.

Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin’s lymphoma. Cancer Control. 2003;10:396–403. https://doi.org/10.1177/107327480301000507.CrossRefPubMed

22.

Wright J, Doan T, McBride R, Jacobson J, Hershman D. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008;98:1197–203. https://doi.org/10.1038/sj.bjc.6604298.CrossRefPubMedPubMedCentral

23.

Morris M, Platell C, Fritschi L, Iacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer. 2007;96:701–7. https://doi.org/10.1038/sj.bjc.6603627.CrossRefPubMedPubMedCentral

24.

O’Connor TL, Edge SB, Kossoff EB, Groman A, Wilding GE, Ademuyiwa FO, et al. Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer. J Geriatr Oncol. 2012;3:320–8. https://doi.org/10.1016/j.jgo.2012.06.006.CrossRef

25.

Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, et al. Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study. JAMA Oncol. 2021;7:1856–61. https://doi.org/10.1001/jamaoncol.2021.4960.CrossRefPubMed

26.

Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166–72. https://doi.org/10.1093/annonc/mdr587.CrossRefPubMed

27.

Shiotsu S, Yoshimura A, Yamada T, Morimoto K, Tsuchiya M, Yoshioka H, et al. Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: a prospective observational study. Front Oncol. 2022;12:904644. https://doi.org/10.3389/fonc.2022.904644.CrossRefPubMedPubMedCentral

28.

Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, et al. Prospective observational study evaluating the prognostic value of the G8 screening tool for extensive-stage small cell lung cancer patients who received programmed death-ligand 1 inhibitor plus platinum-etoposide chemotherapy. Drugs Aging. 2023;40:563–71. https://doi.org/10.1007/s40266-023-01034-4.CrossRefPubMed

Title: Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients
Authors: Keisuke Onoi
Tadaaki Yamada
Kenji Morimoto
Hayato Kawachi
Rei Tsutsumi
Takayuki Takeda
Asuka Okada
Nobuyo Tamiya
Yusuke Chihara
Shinsuke Shiotsu
Yoshizumi Takemura
Takahiro Yamada
Isao Hasegawa
Yuki Katayama
Masahiro Iwasaku
Shinsaku Tokuda
Koichi Takayama
Publication date: 11-03-2024
Publisher: Springer International Publishing
Keywords: Ramucirumab
NSCLC
NSCLC
Cytostatic Therapy
Published in: Targeted Oncology
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-024-01045-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine